A mutational hotspot in CYLD causing cylindromas: A comparison of phenotypes arising in different genetic backgrounds

Acta Dermato-Venereologica

Volumn 93, Issue 6, 2013, Pages 743-745

  Nagy, Nikoletta ^a   Rajan, Neil ^b   Farkas, Katalin ^a   Kinyó, Ágnes ^a   Kemény, Lajos ^a   Széll, Márta ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOID CYSTIC CARCINOMA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CYLINDROMATOSIS GENE; EXON; HAPLOTYPE; HIDRADENOMA; HUMAN; INTRON; NONSENSE MUTATION; PEDIGREE; PHENOTYPE; PRIORITY JOURNAL; TRICHOEPITHELIOMA; TUMOR GENE;

CARCINOMA, ADENOID CYSTIC; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEREDITY; HUMANS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PEDIGREE; PHENOTYPE; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84886439415     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1590     Document Type: Article

References (12)

1. Evans CD. Turban tumour. Br J Dermatol 1954; 66: 434-443.
2. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al. Identification of the familial cylindromatosis tumour suppressor gene. Nat Genet 2000; 25: 160-165.
3. Blake PW, Toro JR. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat 2009; 30: 1025-1036.
4. Sima R, Vanecek T, Kacerovska D, Trubac P, Cribier B, Rutten A, et al. Brooke-Spiegler syndrome: report of 10 patients from 8 families with novel germline mutations: evidence of diverse somatic mutations in the same patients regardless of tumor types. Diagn Mol Pathol 2010; 19: 83-91.
5. Rajan N, Burn J, Langtry, J Sieber-Blum M, Lord CJ, Ashworth A. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression. J Pathol 2011; 224: 309-321.
6. Rajan N, Elliott R, Clewes O, Mackay A, Reis-Filho JS, Burn J, et al. Dysregulated TRK signaling is a therapeutic target in CYLD defective tumors. Oncogene 2011; 30: 4243-4260.
7. Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, Vazquez ME, et al. Mutations in the CYLD gene in Brooke- Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation. J Invest Dermatol 2005; 124: 919-920.
8. Bros M, Dexheimer N, Besche V, Masri J, Trojandt S, Hövelmeyer N, et al. Mutated cylindromatosis gene affects the functional state of dendritic cells. Eur J Immunol 2010; 40: 2848-2857.
9. Trompouki E, Tsagaratou A, Kosmidis SK, Dollé P, Qian J, Kontoyiannis DL, et al. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 2009; 11: 469-476.
10. Scheinfeld N, Hu G, Gill M, Austin C, Celebi JT. Identification of a recurrent mutation in the CYLD gene in Brooke- Spiegler syndrome. Exp Dermatol 2003; 28: 539-541.
11. Gutierrez PP, Eggermann T, Holler D, Jugert FK, Beermann T, Grussendorf-Conen EI, et al. Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumour suppressor gene CYLD underlies different tumours of skin appendages. J Invest Dermatol 2002; 119: 527-531.
12. Rajan N, Langtry JA, Ashworth, Roberts C, Chapman P, Burn J, et al. Tumor mapping in two large multigeneration families with CYLD mutations: implications for patient management and tumor induction. Arch Dermatol 2009; 145: 1277-1284.